With technology/AI taking over administrative and repetitive tasks, human roles will shift towards more strategic, creative, ...

Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Brian Ongioni, chief product officer, uMotif, discusses how AI and machine learning can enhance patient-reported outcomes by ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Brian Ongioni, chief product officer, uMotif, explains how early patient feedback plays a crucial role in shaping digital ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical ...

Cashin, MD, chief medical officer, Novotech, shares insights on how sponsors and CROs can cultivate a “one team” mindset by ...

As clinical research increasingly relies on RWD to enhance trial design and patient insights, tokenization has emerged as a ...

Cashin, MD, chief medical officer, Novotech, emphasizes the importance of proactive communication, strategic alignment, and ...

As wearable ECG technology advances, cardiac safety studies in clinical trials are evolving to capture richer, continuous ...